'Over 1 bn Covishield doses given in India, abroad testimony of its safety'

100 crore Covishield doses have been given in India and abroad which is a testimony of its safety and efficacy, Serum Institute has informed the DCGI

Serum Institute, coronavirus vaccine
Press Trust of India New Delhi
2 min read Last Updated : Jan 04 2022 | 7:56 PM IST

Over 100 crore Covishield doses have been given in India and abroad which is a testimony of its safety and efficacy, Serum Institute has informed the DCGI which had sought more data for granting full marketing approval to the Covid vaccine, official sources said on Tuesday.

Covishield is currently authorized for emergency use in the country. Serum Institute of India (SII), on October 25, had applied to the Drugs Controller General of India (DCGI) seeking regular market authorization for the vaccine.

The drug regulator in December sought more data and documents for it. Following this, Prakash Kumar Singh, the Director, Government and Regulatory Affairs at SII, recently submitted a response along with more data and information.

In addition to the successful completion of phase 2/3 clinical study in India, till now, more than 100 crore doses of Covishield vaccine have been administered to the people in this country and worldwide, Singh is learnt to have stated in the response.

Such a large-scale vaccination with Covishield and containment of COVID-19 infection is in itself a testimony of the safety and efficacy of the vaccine, he said.

"It is a matter of pride for us that we have been a part of the world's largest vaccination drive under the dynamic and visionary leadership of our Prime Minister Narendra Modi.

"Under the kind guidance of Union Health Minister Mansukh Mandaviya, Team Government of India and leadership of our CEO Adar C Poonawalla, Team SII has been working relentlessly to manufacture and supply Covishield for making the world's largest COVID-19 vaccination drive successful," Singh is learnt to have stated in the reply.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusOmicronDelta variant of coronavirusCoronavirus VaccineSerum Institute of India

First Published: Jan 04 2022 | 7:56 PM IST

Next Story